Dragon Pharma Steroids for Sale
Cut Long 300
Substances: Drostanolone Enanthate 100mg, Testosterone Enanthate 100mg, Trenbolone Enanthate 100mg
Cut Mix 150
Substances: Testosterone Propionate 50mg, Drostanolone Propionate 50mg, Trenbolone Acetate 50mg
Sustanon 270
Substances: Testosterone Acetate 20mg, Testosterone Propionate 30mg, Testosterone Phenylpropionate 60mg, Testosterone Isocaproate 60mg, Testosterone Decanoate 100mg
Testo Blend 350
Substances: Testosterone Propionate 50mg, Testosterone Cypionate 100mg, Testosterone Enanthate 200mg
TriTren 150
Substances: Trenbolone Acetate 50mg, Trenbolone Enanthate 50mg, Trenbolone Hexahydrobenzylcarbonate 50mg
About Dragon Pharma
Good old Dragon pharma drugs will not disappoint you. This is probably the most popular company for most of the bodybuilders and athletes all over the world. Dragon pharma is the largest pharmaceuticals manufacturer, which produces high quality steroid products in large volumes, taking all the necessary control in using modern equipment during the manufacturing process. The company has among its employees more than 80 professionals, such as engineers, doctors, pharmacists, etc. Dragon Pharma steroids are on the market for many years, and have already gained credibility. Another indicator of unconditional popularity of the company is the number of fake Dragon Pharma products which nowadays have flooded the steroids’ market.
Top Quality Steroids
Best Shipping Time
Low Prices Guaranteed
Professional Customer Support
Dragon Pharma Europe
Dragon Pharma Reviews
Latest News in Pharmaceutical Industry
Lexicon Genetics Grants Bristol-Myers Squibb Sublicense
Lexicon Genetics Incorporated has granted a non-exclusive sublicense to Bristol- Myers Squibb Company for the use of certain aspects of Lexicon’s positive-negative selection and isogenic DNA technologies. Bristol-Myers Squibb will use the technology for the generation of knockout mice for internal research purposes to gain predictive information about gene products that are valid drug targets Read more about Lexicon Genetics Grants Bristol-Myers Squibb Sublicense[…]
Neurochem And SELECT Therapeutics Collaborate On Alzheimer’s Vaccine
Neurochem, Inc. and SELECT Therapeutics, Inc. have announced the initiation of a collaboration program to advance a novel vaccine intended to prevent the development and the progression of Alzheimer’s Disease. The vaccine will target the prevention of an accumulation of beta- amyloid, a protein that constitutes a major part of plaques in the brain of Read more about Neurochem And SELECT Therapeutics Collaborate On Alzheimer’s Vaccine[…]
AHP And Aventis Pharma Finalise HRT Agreement
American Home Products Corporation and Aventis Pharma have renegotiated their licensing agreement for trimegestone, a modern progestational molecule originated by Aventis for hormone replacement therapy. Under the new agreement, Wyeth-Ayerst Laboratories, the pharmaceutical division of AHP, has exclusive development and worldwide marketing rights for trimegestone for all indications and formulations except transdermal products. The rights Read more about AHP And Aventis Pharma Finalise HRT Agreement[…]
Millennium And Lilly Extend Collaboration
Millennium Pharmaceuticals, Inc. and Eli Lilly and Company have announced a one-year extension of their cardiovascular disease research collaboration. The five-year partnership, originally due to expire in October, will continue at full capacity at least through October of 2001, at which time Lilly has the option to extend for up to two additional years. Since Read more about Millennium And Lilly Extend Collaboration[…]
Ciba Vision Completes Acquisition Of Wesley Jessen
CIBA Vision Corporation, the eye care unit of Novartis AG has completed the merger of WJ Acquisition Corp., an indirect wholly owned subsidiary of Novartis, with and into Wesley Jessen VisionCare, Inc. Wesley Jessen is now an indirect wholly owned subsidiary of Novartis. The acquisition of Wesley Jessen is an important move for CIBA Vision Read more about Ciba Vision Completes Acquisition Of Wesley Jessen[…]
Chiron Patent For HCV Nucleic Acid Testing Upheld
Chiron Corporation has announced that the European Patent Office Technical Board of Appeals upheld the validity of Chiron’s European HCV Patent No. 0 318 216 in amended form. The final ‘216 patent contains broad claims that cover nucleic acid testing (NAT) for hepatitis C virus (HCV) detection and the manufacture, use or sale of such Read more about Chiron Patent For HCV Nucleic Acid Testing Upheld[…]
Generex Receives License From Presspart
Generex Biotechnology Corporation and Presspart Group Limited have entered into a commercial supply agreement for a key component of Generex’s RapidMist device. Under the agreement, Generex will purchase its requirements of pharmaceutical aerosol cans used for the buccal delivery of insulin from UK-based Presspart. Presspart has granted an exclusive license to Generex for the use Read more about Generex Receives License From Presspart[…]
Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration
Exelixis, Inc. has extended and expanded its oncology research collaboration with Bristol-Myers Squibb Company under which the two companies will continue to identify and validate molecular targets implicated in cancer. The original agreement was established for a three-year term in July 2001. Subject to the terms of their amended agreement, Exelixis and Bristol-Myers Squibb have Read more about Exelixis And Bristol-Myers Squibb Extend Oncology Collaboration[…]
ICN Extends Ribapharm Offer, Says No Sweetener
ICN Pharmaceuticals Inc. has again extended its offer to buy drug-maker Ribapharm Inc. until 1 August 2003 and emphasized that shareholders should not expect its $168 million bid to be sweetened. As of July 29, when the offer was set to expire, about 7.7 million Ribapharm shares were tendered for the offer of $5.60 a Read more about ICN Extends Ribapharm Offer, Says No Sweetener[…]
Positive Results For InKine’s Cbp-1011 In Patients With Crohn’s Disease
InKine Pharmaceutical Company announced positive results of its multicenter open-labeled, clinical trial of CBP-1011 in the treatment of patients with mild or moderate Crohn’s disease. Key results of the study included* 80% of patients who completed the study responded to treatment with CBP-1011 using endpoints that were previously defined by the U.S. Food and Drug Read more about Positive Results For InKine’s Cbp-1011 In Patients With Crohn’s Disease[…]
IVAX Acquires Drug In Advanced Clinical Development
IVAX Corporation has entered into an exclusive agreement with Eli Lilly and Company to develop and market the AMPA receptor antagonist, talampanel, worldwide. Phase II clinical trials with talampanel in patients with severe epilepsy not responsive to other drugs have shown positive results and phase III trials in epilepsy will be done to confirm and Read more about IVAX Acquires Drug In Advanced Clinical Development[…]
Genaissance Signs Agreement With Intec
Genaissance Pharmaceuticals, Inc. has entered into an agreement with INTEC Web & Genome Informatics Corporation to market all of Genaissance’s proprietary pharmacogenomics applications and products to pharmaceutical, diagnostic and biotechnology companies located in Japan. “With INTEC W&G as our Japanese sales representative, Genaissance is expanding its potential market reach to a country that is second Read more about Genaissance Signs Agreement With Intec[…]